315 Million People Have
Preclinical Alzheimer’s

Too Little, Too Late!

Imagine if we didn’t treat heart disease until someone had a heart attack.

Alzheimer’s disease likewise develops over decades

Advances in blood biomarkers reveal that early changes are already underway in millions of brains

Too Little, Too Late!

Imagine if we didn’t treat heart disease until someone had a heart attack.

Alzheimer’s disease likewise develops over decades

Advances in blood biomarkers reveal that early changes are already underway in millions of brains

We must intervene early and often
to avert the Alzheimer's crisis

315 Million Worldwide

have preclinical Alzheimer’s, the disease’s first stage

Early Intervention

could prevent or delay nearly half of dementia cases

Identify & Address

modifiable risk factors to help slow or avoid the disease

Impact on the Family

With cases expected to triple by 2060, Alzheimer’s creates profound hardship for individuals and families:

Loss of Independence

Declining thinking skills gradually make daily tasks unsafe or impossible

Strained Relationships

High stress, difficult emotions, and social isolation are rampant

Tolls on Well Being

Family caregivers are at higher risk of illness, including depression and dementia

0th

Leading cause of death over age 65, though NOT a normal part of aging

0%

Of people with Alzheimer’s and related dementias receive care at home

0%

Of Alzheimer’s caregivers report their emotional stress as high or very high

0x

Increased risk for spouses of people with dementia

'Even the smallest of changes can make a difference–and we owe it to our loved ones, our communities, but most of all ourselves, to try.'

— World Alzheimer’s Report 2023: Reducing Dementia Risk, Alzheimer’s Disease International

On the Taxpayer

Medicare spends 3x more per person with Alzheimer’s; Medicaid spends 23x more

On Corporations

Rising unpaid Alzheimer’s caregiving disrupts work and productivity

On Families

Families bear 70% of the total lifetime cost of dementia care

0Million

Americans provide unpaid care for people with dementia

0Billion

Hours of unpaid care provided in 2023, valued at $346.6 billion

0Billion

Total national cost of Alzheimer’s care in 2024. By 2050: Nearly $1 trillion

0Million

Additional care workers needed by 2030—the largest worker gap in the U.S.

'It’s going to bankrupt Medicare if we don’t do something about it.'

— Matthew Baumgart, Alzheimer's Association

Drug Treatment Limitations

Pharma Advancements

Pharmaceutical breakthroughs have led to first-in-kind medications targeting Alzheimer’s underlying pathology.

Amyloid-Targeting Medications

FDA-approved donanemab-azbt (Kisunla, 2024), lecanemab (Leqembi, 2023) and aducanemab (Aduhelm, 2021, discontinued in 2024) were shown to reduce brain amyloid deposits, a main feature of Alzheimer’s, and slow disease progression.

Promising, yes. But these drug therapies have significant limitations:

Cost

At $25k+/year, immunotherapies have ``low long-term value`` (ICER, 2024)

Side Effects

Require close monitoring and brain imaging; amyloid-related imaging abnormalities (ARIA) include brain swelling and bleeding

Reach

Fewer than 17% of those with early-stage AD meet eligibility criteria for anti-amyloid drugs

Effectiveness

These drugs can slow symptom progression but do not stop, reverse, or cure Alzheimer’s

Lifestyle Challenges

Awareness

Prevention should begin early but adults fail to link lifestyle and risk

Access

With few Alzheimer’s prevention clinics and little primary-care training, millions lack access to care

Cost

Specialty care is expensive; many uninsured avoid even primary care

Adherence

Behavior change is a long, challenging process, especially for higher-risk populations

'Effective interventions exist, but they are not delivered at scale to everyone that would benefit from them.'

— Dementia Prevention, Intervention and Care: 2024 Report of the Lancet Commission

Our Solution:

RetainYourBrain™

Manage your risk factors for cognitive decline

Learn More